Organicell Regenerative Medicine, Inc

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL), a company focused on the development and commercialization of regenerative therapies, has released its quarterly report, revealing some interesting statistics and trends. In this 1500-word article, we’ll examine the key findings from the report and what they mean for the company’s future prospects. Gross Profit …

Organicell Regenerative Medicine, Inc. Reports Decreased Gross Profit and Increased Cost of Revenues in Quarterly Report Read More »

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL) recently reached a settlement with Mr. Pepock and Ms. Yourke, resolving a legal dispute and leading to the repurchase of 24,800,001 shares of common stock for $500,000. The settlement marks the end of a contentious legal battle, as the repurchased shares were transferred back to …

Organicell Repurchases 24.8 Million Shares and Resolves Lawsuit with Pepock and Yourke Read More »

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL) recently raised $100,000 through the sale of more than 4.4 million shares at a price of $0.02244 each. The funds raised will be used for working capital and general corporate purposes. In parallel, the company has undergone significant executive changes, settled litigation by repurchasing 24.8 …

Organicell Regenerative Medicine Raises $100,000 from Share Sale Amid Executive Shake-Up and Litigation Settlements Read More »

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL) recently released its quarterly report, revealing a net loss of $4,277,954 for the six months ended April 30, 2023. The company also stated an accumulated deficit of $54,799,260 and a stockholders’ deficit of $138,908 at the end of April 2023. Organicell is bolstering efforts to …

Organicell Regenerative Medicine Inc. Reports Net Loss of $4,277,954 for the First Half of 2023 Read More »

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL), a bio-pharmaceutical company specializing in the research, development, and commercialization of regenerative medicine therapies, has released their quarterly report for Q2 2023. During the six-month period ended April 30, 2023, Organicell reported revenues of $1.9 million, representing a strong financial performance for the company. Strong …

Organicell Regenerative Medicine, Inc.’s Revenue Reaches $1.9 Million for First Six Months of Fiscal Year Read More »